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Summary Smoking cessation is the most effective way to reduce the risk of
developing chronic obstructive pulmonary disease (COPD). It prevents or delays the
development of airflow limitation and also reduces its progression. The objective of
this study was to systematically review the effects of interventions for smoking
cessation in people with COPD. Comprehensive searches of electronic and internet
databases were carried out from 1966 to March 2002, using the Cochrane Airways
Group search strategy. The reference lists of all selected randomized trials and
relevant reviews were inspected for additional published reports and citations of
unpublished research. We evaluated the efficacy of behavioural interventions (e.g.
counselling), pharmacotherapy (nicotine replacement therapy and non-nicotine
therapy such as bupropion), and combinations of both. The main clinical outcome
measure was prolonged abstinence after at least 6 months, confirmed by a
biochemical test. Five trials comprising 6491 patients with COPD were included.
Results of the Lung Health Study show that, by using an intensive behavioural
(relapse prevention) programme combined with nicotine replacement therapy,
prolonged abstinence rates are not only significantly higher compared with no
intervention, but the difference in efficacy was sustained for over 5 years. A 12-week
treatment course with bupropion sustained release combined with individual
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counselling, however, did not result in significantly higher prolonged abstinence
rates after 12 months. Present evidence suggests that the most effective
intervention for prolonged smoking cessation in patients with COPD is the
combination of nicotine replacement therapy, coupled with an intensive, prolonged
relapse prevention programme.
& 2004 Published by Elsevier Ltd.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality world-
wide, and results in an economic and social burden
that is both substantial and increasing.1 COPD
prevalence, morbidity and mortality vary across
countries and across different groups within coun-
tries, but are in general directly related to the
prevalence of tobacco smoking.1 In the developed
world, smoking accounts for at least 75% of COPD
cases.2,3 Furthermore, smoking cigarettes acceler-
ates the rate of decline in pulmonary function
beyond that usually seen with aging.4–10 Fletcher
et al.,6 for instance, showed that, in non-smokers,
the mean decline in forced expiratory volume in 1 s
(FEV1) due to normal aging is about 30ml per year
in adults, whereas it averages more than 50ml per
year in susceptible smokers. Other studies have
also observed increased rates of decline, although
the rates vary.4,11
Smoking cessation is the most effective way to
reduce the risk of developing COPD.9,12 It can
prevent or delay the development of airflow
limitation and also reduce its progression. Up until
now, smoking cessation is the only intervention that
has shown to reduce the rate of FEV1 decline for
both men and women.4,5,9,13,14 Several studies have
examined the time frame during which benefits of
smoking cessation may be observed. In general,
results indicate that the onset of the reduction in
rate of loss of FEV1 occurs early after cessation. In
the study conducted by Burchfiel et al.,4 rate of
FEV1 decline was not associated significantly with
the length of time since quitting, indicating that
smoking cessation may lead to a rapid return to the
usual age-related decline seen in people who have
never smoked.4,9 These observations support the
hypothesis of a bronchoconstrictive or inflamma-
tory effect of smoking that could be reversible to
some degree soon after exposure ceases.4,5,8,9
Although smoking cessation is widely mentioned
as the most important measure in patients with
COPD, little is known about the effectiveness of
existing smoking cessation interventions specifi-
cally in these patients. The objective of this study
was to systematically review the effects of inter-
ventions for smoking cessation in patients with
COPD. We evaluated the efficacy of behavioural
interventions, pharmacological interventions and
combinations of both.
Methods
Selection of studies for inclusion
Study design
Only randomized trials were included in this
systematic review. We included studies on smoking
cessation that were part of a broader experiment
(i.e. use of a factorial design) only if it was possible
to extract data on the effects of the smoking
cessation component specifically, and if the nature
of the experimental and control intervention(s) was
explicitly stated.
Population
Because COPD is defined on the basis of airflow
limitation, we included studies in which the study
population consisted of smokers with largely
irreversible airflow obstruction. The presence of
COPD had to be assessed according to guidelines for
the diagnosis of COPD (e.g. guidelines from the
American Thoracic Society [ATS],15 the British
Thoracic Society,16 the European Respiratory So-
ciety17 and the Global Initiative for Chronic
Obstructive Lung Disease2) or by a respiratory
clinician.
Interventions
We included trials that studied the effects of an
intervention to assist smokers in making a quit
attempt and helping them avoid relapse. The
experimental and control intervention(s) could
include any behavioural intervention (i.e. self-help
interventions [the use of a pamphlet, audiotape,
videotape, mailed information or a computer
programme], individual counselling, group counsel-
ling, or (proactive) telephone counselling, with or
without the use of pharmacotherapy (nicotine
replacement therapy, non-nicotine therapy such
as bupropion, or both).
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Types of outcome measures
The main clinical outcome measure was prolonged
abstinence after at least 6 months, confirmed by a
biochemical test (e.g. breath carbon monoxide,
urinary cotinine). Point prevalence abstinence
rates were used if prolonged abstinence rates were
not assessed and could not be retrieved. Partici-
pants who were lost to follow-up, or had dropped
out, were regarded as being smokers.
Search strategy
Electronic databases
The Cochrane review provides a more detailed
description of the search terms used and the
electronic databases that were searched.18
Reference tracking
We inspected the reference lists of all selected
studies and relevant reviews19–21 for additional
published reports and citations of unpublished
research. In addition, we screened abstract books
of relevant conferences and symposia from 1999
until November 2003 (European Respiratory So-
ciety, ATS and the annual meetings of the European
and American Society for Research on Nicotine and
Tobacco).
Internet databases
We also searched the following online publicly
accessible registers of clinical trials:22 Clinical-
Trials.gov,23 TrialsCentral.org,24 Controlled-Trials.-
com and the National Research Register, Issue 3,
2003.
Personal communications
The first author or principal investigator of identi-
fied papers was contacted through dissemination of
a standard e-mail or letter. It explained the
purposes of the review and specified the additional
data that we required.
Data extraction
Two reviewers (RvdM, EJW) independently checked
for relevance all references that were retrieved by
our literature search, and selected the studies to
be included in the systematic review. The same
authors extracted data independently using a
standardized form. A consensus method was used
to resolve disagreements concerning selection and
inclusion of trials, and a third reviewer (RO) was
consulted if disagreements persisted. The data-
extraction form was pre-tested using two rando-
mized trials on smoking cessation in smokers
without a chronic disease.
For each trial, two reviewers (RvdM and EJW)
extracted the following data using a standardized
form: (1) first author and year of publication; (2)
comparisons studied; (3) study methods (setting,
randomization, length of follow-up); (4) study
population (number randomized and diagnostic
criteria used); (5) intervention(s); and (6) definition
of abstinence (including validation technique
used).
Methodological quality assessment
To assess the methodological quality of selected
trials, we used the internal validity criteria from
the Delphi list.25 Two reviewers (RvdM and EJW)
assigned a score for reported compliance with each
of the following criteria: method of randomization
described (use of random [unpredictable] assign-
ment sequence), treatment allocation concealed
(assignment generated by an independent person
not responsible for determining the eligibility of
the patients), specification of eligibility criteria,
comparability regarding prognostic indicators (e.g.
level of nicotine dependence, number of cigarettes
smoked per day), (attempt to) patient blinding,
(attempt to) blinding of therapist, (attempt to)
blinding of outcome assessor, presentation of point
estimates and measures of variability for primary
outcome measures, and intention-to-treat analysis
performed. The items were scored as ‘‘yes’’ (1
point), ‘‘no’’ or ‘‘unclear’’ (both 0 points). A total
score for the methodological quality of each study
was calculated by summing up the number of
positive criteria (range 0–9), higher scores indicat-
ing a lower likelihood of bias.26
For studies published in languages other than
English, German or Dutch, the help of a translator
of the Cochrane Airways Group was obtained (see
acknowledgements). If an article did not contain
enough information on methodological criteria (i.e.
if one or more criteria were scored ‘‘unclear’’), the
authors were contacted for additional information.
Quantitative data synthesis
Measures of effect
We used Review Manager 4.2.226 to estimate the
summary statistics (relative risks [RR], risk differ-
ences [RD] and corresponding 95% confidence
intervals [95% CI]). We included the RD because it
reflects the absolute change in risk with the
intervention. Abstinence rates were calculated on
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the basis of the number of participants randomized
to an intervention.
Results
Identification and description of eligible
trials
We retrieved 30 papers out of 365 references. The
first selection was based on titles, keywords and
abstracts, and resulted in both reviewers including
13 studies. Checking the reference lists of identi-
fied studies and relevant reviews resulted in the
inclusion of another 17 studies. The final selection
was based on full papers (30 papers, 29 studies),
and resulted in exclusion of 24 papers that seemed
relevant but did not meet all inclusion criteria, and
inclusion of six papers that met the inclusion
criteria and contributed to the review. They
referred to five different trials, comprising 6491
patients with COPD (5887 of these patients parti-
cipated in the Lung Health Study), conducted in the
USA, Canada and Denmark between 1991 and
2001.12,27–30 The characteristics of the trials are
described in Table 1.
Quantitative data synthesis
Because studies were clinically heterogeneous with
regard to study population (severity of the obstruc-
tion) and types of interventions, abstinence rates
were not pooled.
Comparison of behavioural interventions
We found three trials comparing different beha-
vioural interventions.27–29 Figure 1 shows the forest
plots with (point prevalence and prolonged) absti-
nence rates, RR and RD for the comparisons
studied. Brandt et al.28 evaluated whether use of
the words ‘‘smoker’s lung’’ instead of traditional
terminology when talking to patients with COPD
changed their smoking habits. Although use of the
words ‘‘smoker’s lung’’ increased abstinence from
smoking, the effect did not reach statistical
significance (RD¼ 0.16, 95% CI –0.07 to þ 0.38;
RR¼ 1.98, 95% CI 0.74 to 5.31). The trial conducted
by Pederson et al.29 showed that individual coun-
selling responsive to the patients’ needs and
questions combined with the use of a self-help
smoking cessation manual was not significantly
more effective compared with physician advice to
quit smoking (RD¼ 0.11, 95% CI –0.08 to þ 0.29;
RR¼ 1.67, 95% CI 0.68 to 4.11). Crowley et al.27
compared the efficacy of different behavioural
reinforcement schedules. Contingent reinforce-
ment with lottery tickets for reduced breath
carbon monoxide increased quit rates compared
with only reimbursing patients when they came in
for their planned visits, although the difference
was not statistically significant (RD¼ 0.10, 95% CI –
0.11 to þ 0.31; RR¼ 2.50, 95% CI 0.29 to 21.61).
The trial also failed to find a statistically significant
difference in prolonged abstinence rates between
contingent reinforcement with lottery tickets for
reduced breath carbon monoxide compared with
contingent reinforcement for self-report of re-
duced smoking (also with lottery tickets) (RD¼ –
0.08, 95% CI –0.36 to þ 0.19; RR¼ 0.67, 95% CI 0.18
to 2.54) (Fig. 1).
Combination of a behavioural intervention with
pharmacotherapy compared with no intervention
The Lung Health Study12 evaluated the effect of an
intensive smoking cessation intervention (combined
with either the inhaled bronchodilator ipratropium
bromide or placebo) on the rate of decline in FEV1.
The comparison group, termed ‘‘usual care’’ by the
authors, received no definitive smoking intervention.
The smoking intervention consisted of (1) 12 group
sessions in the first 10 weeks of the study (the
frequency of meetings starting at four per week and
gradually declining); (2) nicotine gum provided at no
cost (the authors did not describe the prescribed
dose and duration); and (3) a maintenance pro-
gramme for people who quit smoking aimed at
preventing relapse by teaching coping skills for
problems such as stress and increases in body weight.
Relapses were individually treated as soon as they
occurred if the participant was willing. Smokers
thought to be at high risk for COPD as indicated by
the presence of mild airways obstruction, which the
Lung Health Study Research Group defined as a (pre-
bronchodilator) ratio of FEV1 to forced vital capacity
(FVC) of 70% or less, were eligible for participation.
Smokers were excluded if they regularly used
physician-prescribed bronchodilators.
In Fig. 2, point prevalence and prolonged absti-
nence smoking cessation rates from the Lung Health
Study are presented.12 Results indicate that the use
of an intensive smoking cessation programme
(combined with ipratropium bromide) is signifi-
cantly more effective after 12 months’ follow-up
than no intervention in helping smokers to quit
(RD¼ 0.26, 95% CI 0.23 to 0.28; RR¼ 3.85, 95% CI
3.30 to 4.48). This difference remained statistically
significant throughout the 5-year follow-up
(RD¼ 0.16, 95% CI 0.14 to 0.18; RR¼ 4.01, 95% CI
3.25 to 4.93). The combination of the smoking
intervention with a placebo bronchodilator yielded
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Table 1 Characteristics of included studies.
Study Comparison(s) Methods Study population Intervention(s) Definition of abstinence
and validation technique
Anthonisen
et al.12
1. Advice to quit by physicianþ
group counsellingþ nicotine
chewing gumþ ipratropium
bromide vs. no intervention
(usual care)
2. Advice to quit by physicianþ
group counsellingþ nicotine
chewing gumþ inhaled placebo
vs. no intervention (usual care)
Country: USA and Canada
Setting: 10 clinical centres
Recruitment: media publicity,
mass mailings, worksite and
public screening
Randomization: block
randomization, separately
performed for each clinic
Length of follow-up: 1, 2, 3, 4, 5,
11 years
Number in trial: 5887 current
smokers
Diagnosis: asthma (7.2%),
bronchitis (29.9%),
emphysema (3.2%)
Cigarette consumption: 31
cigarettes/day
Therapists: physician and
health educator
1. Advice to quit by physician (one session)þ
group counselling (12 sessions in 10 weeks;
duration not stated)þ nicotine gum (dose and
duration not stated)þ ipratropium bromide
(dose and duration not stated)
2. Advice to quit by physician (one session;
duration not stated)þ group counselling
(12 sessions in 10 weeks)þNRT (gum, dose
and duration not stated)þ inhaled placebo
bronchodilator
3. No intervention (usual care)
Definition of abstinence:
abstinence at each of annual
visits 1–5
Validation technique: expired
air CO and salivary cotinine
Brandt
et al.28
Use of the word ‘‘smoker’s lung’’
þ information material vs. use of
the word ‘‘chronic bronchitis’’
Country: Denmark
Setting: general medical ward
of hospital
Recruitment: medical ward of
the department of Internal
Medicine, Faaborg
Randomization: method not
stated
Length of follow-up: 1 week,
3 months, and 1 year
Number in trial: 56 smoking
patients with COPD admitted
to a general medical ward
within the years 1994–1995
Diagnosis: criteria for COPD
described as ‘intermittent or
chronic dyspnoea, coughing,
changing grades of bronchial
obstruction and/or secretion
problems’
Cigarette consumption:
cigarette/day not stated
1. Use of the word ‘‘smoker’s lung’’
(Danish: ‘‘rygerlunger’’) instead of
chronic bronchitis when talking to
patientsþ information material (brochure).
2. Use of the term ‘‘chronic bronchitis’’
when talking to patients
Definition of abstinence:
self-reported smoking cessation
at 1 year
Validation technique: expired
air CO
Crowley
et al.27
1. Individual counsellingþ
information material (brochure)
þ nicotine chewing gumþ
contingent reinforcement for
reduced breath carbon
monoxide vs. individual
counsellingþ information
material (brochure)þ nicotine
chewing gumþ reimbursement
for visits
2. Individual counsellingþ
information material (brochure)
þ nicotine chewing gumþ
contingent reinforcement for
Country: USA
Setting: home visits
Recruitment: screening of
patients presenting to a medical
clinic
Randomization: block randomization
after pre-stratification on sex and
FEV1 (method of randomization not
stated)
Length of follow-up: 6 months
Number in trial: 49 current
smokers
Diagnosis: 3 patients (6.1%)
with early COPD (FEV1¼
70–90%, and FEV1/FVCo70%),
47 patients (93.9%) had late
COPD (FEV1o70%)
Cigarette consumption:
not stated
1. Anti-smoking encouragement (one session,
30min during baseline)þ information material
(brochure)þNRT (gum, 2mg/piece, up to 30
pieces/day, days 11–75)þ contingent
reinforcement for reduced breath CO
(lottery tickets, reinforce if CCO meets
criterion and reinforcement is scheduled,
total not stated, days 1–85)
2. Anti-smoking encouragement (one session,
30min during baseline)þ information material
(brochure)þNRT (gum, 2mg/piece, up to 30
pieces/day, days 11–75)þ reimbursement for
visits (lottery tickets, equal to pair-mates’
earnings, days 1–85)
Definition of abstinence:
self-report of not smoking
during the last 30 days of
the study
Validation technique: expired
air CO (CCOo10 on at least 28
of the last 30 days)
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Table 1 (continued)
Study Comparison(s) Methods Study population Intervention(s) Definition of abstinence
and validation technique
reduced breath carbon
monoxide vs. individual
counsellingþ information
material (brochure)þ nicotine
chewing gumþ reinforcement
for self-report of reduced
smoking
3. Anti-smoking encouragement (one session,
30min during baseline)þ information material
(brochure)þNRT (gum, 2mg/piece, up to 30
pieces/day, days 11–75)þ contingent
reinforcement for self-report of reduced
smoking (lottery tickets, reinforce
if report is ‘‘none since last visit’’ and
reinforcement is scheduled, days 1–85)
Pederson
et al.29
Advice to quit by physicianþ
self-help smoking cessation
manualþ individual counselling
responsive to the patients’
needs and questions vs. advice
to quit by physician
Country: Canada
Setting: chest unit of a 660-bed
teaching hospital
Recruitment: cigarette smoking
patients with previously
diagnosed COPD admitted to a
chest unit
Randomization: method not
stated
Length of follow-up: 3 and
6 months
Number in trial: 74 current
smokers admitted to a
hospital.
Diagnosis: chronic bronchitis
(43%) and emphysema
(57%) according to
ACCP-ATS criteria
Cigarette consumption: 93%
of participants smoked 10
cigarettes/day or more
1. Advice to quit by physician (one session
before admission; duration not stated)þ
self-help smoking cessation manualþ
individual counselling responsive to the
patients’ needs and questions (3–8 sessions,
15–20min per session)
2. Advice to quit by physician before
admission (duration not stated)
Definition of abstinence:
self-reported smoking status
assessed at 3 and 6 months by
means of telephone interview
Validation technique: COHb
analysis from blood samples
Tashkin
et al.30
Bupropion SRþ individual
counselling vs. placebo
bupropionþ individual
counselling
Country: USA
Setting: 11 centres
Recruitment: print and radio
advertisement
Randomization: block
randomization (code provided
by Glaxo Wellcome), using
block sizes of four stratified by
centre (method of randomization
not stated)
Length of follow-up: 12 weeks and
26 weeks
Number in trial: 411 smokers.
Diagnosis: patients with
COPD staged I or II
(ATS-criteria)
Cigarette consumption: 28.2
cigarettes/day during
previous year
1. Bupropion SR (150mg once daily for days
1–3, twice daily for days 4–84)þ individual
counselling (one telephone session, nine
individual sessions at week 1–7, 10 and 12;
duration not stated).
2. Placebo bupropion (1/1 ratio)þ individual
counselling (one telephone session,
nine individual sessions at week 1–7, 10 and
12; duration not stated)
Definition of abstinence:
continuous abstinence from
smoking defined by
participants being
continuously abstinent
during weeks 4–12,
and having a diary cigarette
count of zero
during weeks 13–26
Validation technique:
expired air CO (10 ppm
or less at week 26)
ACCP, American College of Chest Physicins; ATP, American Thoracic Society; CO, carbon monoxide; COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; NRT, nicotine replacement therapy.
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almost identical outcomes compared with no inter-
vention (after 12 months: RD¼ 0.25, 95% CI 0.23 to
0.28; RR¼ 3.81, 95% CI 3.27 to 4.44; after 5 years
RD¼ 0.17, 95% CI 0.15 to 0.19; RR¼ 4.19, 95% CI
3.41 to 5.16). Murray et al.31 have recently shown
that the benefit in reducing FEV1 decline between
the smoking intervention programme and no inter-
vention (referred to by the authors as ‘‘usual care’’)
persisted 11 years after the start of the Lung Health
Study.12
Bupropion compared with placebo medication
Tashkin et al.30 reported on the efficacy of
bupropion sustained release (SR) for smoking
cessation. The study population consisted of cur-
rent smokers with a ratio of FEV1 to FVC of 70%
or less and presence of clinically defined COPD.
They defined severity of COPD according to COPD-
staging guidelines from the ATS (ATS; stage
I¼ FEV1X50% predicted, and stage II¼ FEV1 be-
tween 35% and 50% of predicted). Figure 3 indicates
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Figure 1 Abstinence rates, relative risks and risk differences for the comparison of behavioural interventions.
Figure 2 Abstinence rates, relative risks and risk differences for the combination of a behavioural intervention and
pharmacotherapy compared with no intervention.
Figure 3 Abstinence rates, relative risks and risk differences for bupropion compared with placebo.
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that the combination of bupropion SR 300mg/day
for 12 weeks and 10 individual counselling sessions
resulted in significantly higher prolonged absti-
nence rates after 26 weeks compared with placebo
combined with the same behavioural intervention
(RD¼ 0.07, 95% CI 0.00 to 0.13; RR¼ 1.74, 95% CI
1.01 to 3.00).
However, data from the same study (although not
presented in their publication) showed that, after
12 months, the difference between bupropion and
control group disappeared. After 12 months, 21
smokers (10%) from the bupropion group were still
abstinent from smoking, compared with 17 (8%)
smokers from the control group (RD¼ 0.02, 95% CI –
0.04 to 0.07; RR¼ 1.21, 95% CI 0.66 to 2.23).20
Methodological quality
Table 2 shows the results of the methodological
quality assessment. In general, the scores for
methodological quality varied between 2 and 9
points. Although one study30 had a maximum score
of nine, indicating a low likelihood of bias, the
scores of the other four studies varied between 2
and 5 points. Two of the five studies had an
acceptable quality score (X5 points). The most
prevalent methodological flaws were associated
with inadequate allocation concealment, and the
blinding of the outcome assessor, the therapist and
the patient. Although four studies reported that a
method of randomization was carried out, only one
study30 reported the randomization procedure in
sufficient detail to determine whether a satisfac-
tory attempt to control selection bias had been
made. All trials used some form of validation of
self-reported smoking cessation. Validation of
abstinence was carried out by blinded methods
(measurement of metabolites in body fluids) in two
trials,12,29 although, in one trial, biochemical
verification was sought in a random sample of
quitters.29 The other three trials measured carbon
monoxide in expired air.27,28,30
Discussion
This systematic review shows that, until now, only
five randomized trials, comprising 6491 patients
with COPD, have evaluated the efficacy of smoking
cessation interventions directed specifically at
patients with COPD. Because the included trials
were clinically heterogeneous with regard to study
population (severity of the obstruction) and the
type of intervention that was studied, pooling of
ARTICLE IN PRESS
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data was impossible. In three trials, the efficacy of
different behavioural interventions for smoking
cessation was assessed.27–29 The three trials,
namely, use of the words ‘‘smoker’s lung’’ instead
of traditional terminology when talking to patients
with COPD,28 contingent reinforcement for smoking
cessation27 and individual support and encourage-
ment responsive to the patients’ needs and ques-
tions,29 all failed to find a statistically significant
difference in efficacy, even though each showed a
trend in favour of the intervention. The number of
patients in each trial was small, however, and the
CI wide, so it remains possible that a clinically
useful effect might have been missed.
In the Lung Health Study,12 5887 smokers who
were thought to be at high risk for COPD (pre-
bronchodilator FEV1 to FVC ratio of 70% or less)
participated and tried to quit smoking. Eligible
smokers were not recruited through healthcare
professionals but by using media publicity, mass
mailings and worksite and public screening. As a
result, most participants did not have a history of
physician-diagnosed bronchitis or emphysema. Re-
sults of the Lung Health Study12 showed that the
combination of nicotine chewing gum and intensive
individual counselling for a sustained period (5
years) significantly increased smoking cessation.
Results from the Cochrane review on nicotine
replacement therapy for smoking cessation32 in-
dicate that there is strong evidence for the efficacy
of nicotine gum as part of a strategy to promote
smoking cessation in smokers in general. Also, the
absolute probability of not smoking at 6–12 months
was greater in trials that provided intensive
additional support, particularly with nicotine
gum, although the result was not statistically
significant.32 As the experimental intervention in
the Lung Health Study resulted in high prolonged
abstinence rates (even after 5 years), the question
arises whether it is feasible to implement this
intervention in daily practice. We think it is not, for
two reasons. Many of the patients had mild or
asymptomatic airways disease, and had not neces-
sarily presented to a health professional outside
the context of this study. Secondly, the intervention
is very resource intensive. Smoking cessation
programmes would need to be established in which
healthcare professionals had the time and re-
sources to implement an intensive intervention
(i.e. 12 sessions during the first 10 weeks, com-
bined with visits at 4-month intervals for the
remainder of the 5 years), and retain the ability
to respond rapidly to relapses.
On the basis of the medium-term results of the
study conducted by Tashkin et al.30 (i.e. after 26
weeks), one would conclude that bupropion is an
effective aid in smoking cessation for patients with
mild-to-moderate COPD. However, when the results
of this study were evaluated after 12 months, the
efficacy of bupropion compared with placebo could
not be sustained.20 The number of participants who
relapsed increased significantly faster over time in
the bupropion group than in the placebo group. The
prolonged abstinence rates declined from week 26
to 52 by 6% in the bupropion group (from 16% at
week 26 to 10% at week 52) compared with only 1%
in the placebo group (from 9% after week 26 to 8%
after week 52).20,30
Bupropion has now been licensed for use in
smoking cessation in the USA and many countries of
the European Union. In a recent Cochrane review
update, Hughes et al.19 identified 16 randomized
trials in which the efficacy of bupropion was
compared with placebo medication (including the
study conducted by Tashkin et al.30). In only half of
the 16 trials did bupropion result in significantly
higher prolonged abstinence rates after at least 6
months, compared with placebo medication.19
Bupropion acts on sites in the central nervous
system to reduce withdrawal symptoms.33 This drug
probably does not attenuate or block the reinfor-
cing effects of nicotine. The results of the
systematic review by Hughes et al.19 raise the
possibility that bupropion will provide relief of
associated smoking cessation symptoms and, in the
long term, will most likely be of limited efficacy. In
this respect, it would be interesting to evaluate the
efficacy of bupropion without (intensive) beha-
vioural support, as the follow-up time during which
bupropion is significantly more effective compared
with placebo treatment could well be extended by
prolonged behavioural treatment.
Conclusion
To summarize, the results of this systematic review
indicate that, with the exception of the combined
use of pharmacotherapy to reduce craving and
withdrawal, with intensive individual counselling
for a sustained period, the success of other smoking
cessation interventions in patients with COPD is
low. This is consistent with the commonly held
assumption that continued smoking in the presence
of established COPD and aggravating symptoms is
an indication that these patients are particularly
addicted to nicotine,34 and would already have quit
smoking if they could. Tashkin et al.30 evaluated
whether bupropion SR resulted in higher abstinence
rates in patients with stage I COPD (FEV1X50%
predicted) compared with patients with stage II
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COPD (FEV1 between 35% and 50% of predicted).
Prolonged abstinence rates after 26 weeks were
lower in patients with more severe COPD, although
this difference was not statistically significant.
Published studies on smoking cessation show that
about 70–80% of the motivated (non-chronically ill)
smokers relapse within the first 12 months.35–37
Whether quit rates are lower in patients with
severe COPD compared with healthy smokers or
smokers with mild COPD remains unknown.
Future research might address the short, inter-
mediate and long-term effects of a range of cost-
effective strategies for smoking cessation in pa-
tients with COPD, and also whether the effects of
smoking cessation interventions in ‘‘healthy’’ smo-
kers can be extrapolated to smokers with COPD.
This would involve trials in which the efficacy of
smoking cessation strategies in smokers without a
chronic illness is compared with the efficacy in
smokers with COPD.
Practice points
* Smoking cessation is the most important
therapeutic goal in COPD patients who still
smoke.
* As people with early COPD may be asymp-
tomatic, all smokers should be considered
for smoking cessation interventions.
* The combination of nicotine chewing gum
and intensive individual counselling for a
sustained period significantly increases
prolonged abstinence from smoking in
patients with mild airways obstruction;
however, this approach is resource inten-
sive.
* Treat relapse as soon as possible (prefer-
ably as soon as it occurs).
* The combination of bupropion and beha-
vioural counselling is effective during the
first 6 months after the target quit date;
however, this effect is not sustained at 12
months.
* The use of bupropion alone for smoking
cessation in COPD without an intensive
behavioural program is not supported on
present evidence.
Research directions
* RCTs evaluating the short, intermediate
and long-term effects of existing pharma-
cotherapies and behavioural therapies for
smoking cessation in patients with COPD.
* Research comparing the dependence on
nicotine in patients with COPD at different
stages of the disease.
* RCTs evaluating the short, intermediate
and long-term effects of existing smoking
cessation interventions in patients with
severe COPD compared with patients with
mild or moderate COPD, healthy smokers,
or both.
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